



KOLINPHARMA®

LEADER TO HEALTH

KOLINPHARMA® LAUNCHES DOLTENDIX®

THE NEW CERTIFIED, PATENT PENDING FOOD SUPPLEMENT

formulated by Kolinpharma's internal R&D department

Milan, 18th June 2021

KOLINPHARMA®, Innovative SME operating in the nutraceutical sector, announces the launch of the new food supplement owned by Kolinpharma **DOLTENDIX®** which will enrich the product portfolio for the orthopedic-physiatric area of the **KipBlue** line (which already includes the XINEPA®, XINEPA products easy®, MILESAX®, DOLATROX® and DOLATROX® hcc).

DOLTENDIX®, whose formulation was developed by the internal Research and Development department, is a food supplement formulated for the "well-being of the tendons" based on bioactive peptides from collagen, astaxanthin, trans-resveratrol and vitamin C. Like the others references in the portfolio, all developed internally, DOLTENDIX® uses high quality raw materials, technologically advanced and supported by in-depth scientific studies.

In line with the particular attention that Kolinpharma pays to consumer needs, DOLTENDIX® is **Halal, Kosher, Play Sure Doping Free** certified, and is also **milk-free, lactose-free** and **gluten free**.

The product will be presented to physicians by the highly specialized network of Medical-Scientific representatives (MSRs).

Confirming the innovative potential of the new formulation, the Company announces the filing of a patent application in Italy.

Rita Paola Petrelli, President of KOLINPHARMA®, commented: *"The launch of the new food supplement DOLTENDIX® highlights the commitment, tenacity and positive results achieved by all the collaborators who constantly devote their energies to growth of Kolinpharma in the nutraceutical sector. The new product belongs to the orthopedic-physiatric line and has great potential for development in the related supplement market. Our great attention to high quality raw materials, our values linked to sustainability for technological innovation and for the protection and inclusion of the consumer are confirmed once again by the Halal, Kosher, Play Sure Doping Free certifications which already cover all our products "*.

KOLINPHARMA S.p.A.
SEDE OPERATIVA
Corso Europa, 5
20020 Lainate (MI)
Tel. +39 02 94324300
Fax +39 02 93571446

SEDE LEGALE
Via Larga, 8
20122 Milano

info@kolinpharma.com
C.F. e P. IVA 08331990963
Cap. soc. € 1.639.571 i.v.
R.E.A. MI-2018304



www.kolinpharma.com



KOLINPHARMA®

LEADER TO HEALTH

This press release is available online on the corporate website www.kolinpharma.com, in the Investor Relations > Financial Press Releases section, and on www.emarketstorage.com.

* * *

KOLINPHARMA® S.p.A., founded in 2013, is an innovative SME operating in the nutraceutical sector and specialized in research and development, carried out internally and in collaboration with the most prominent Italian universities. The Company's products are made with innovative and natural raw materials and are intended to support pharmacological treatments mainly for pathologies in the orthopedic-physiatric and urological-gynecological fields. The effectiveness of the products is proven through numerous scientific evidence, by carrying both in vitro and clinical studies and the publication of the results in international technical-scientific journals. KOLINPHARMA® distributes products with its own brand throughout the Italian territory through a qualified network of 89 Medical-Scientific representatives (MSRs), specialized professionals with degrees in scientific disciplines. The IMS have the role of promoting the nutraceutical products of KOLINPHARMA® directly by the medical professionals, focusing on the awareness of medical specialists. The Company's direct customers are wholesalers, who distribute to pharmacies and parapharmacies throughout Italy.

KOLINPHARMA® holds 5 patents in Italy, 5 in the USA, 1 in Israel, 12 patents in the main European countries and 12 certifications, of which 5 on the company and 7 on products.

Isin ordinary shares IT0005322950 - Bloomberg code KIP IM - Reuters code KIP.MI

Contacts

IR Top Consulting Investor Relations

ir@irtop.com

Media Relations:

Domenico Gentile

d.gentile@irtop.com

Via Bigli, 19 - 20121 Milano

Tel.: +39 02 4547 3883/4

EnVent Capital Markets Ltd. Nominated Adviser (NomAd)

Francesca Martino

fmartino@enventcapitalmarkets.co.uk

42 Berkeley Square – London W1J 5AW

KOLINPHARMA Issuer

Rita Paola Petrelli

Investor Relator

investorrelator@kolinpharma.com

KOLINPHARMA S.p.A.
SEDE OPERATIVA
Corso Europa, 5
20020 Lainate (MI)
Tel. +39 02 94324300
Fax +39 02 93571446

SEDE LEGALE
Via Larga, 8
20122 Milano

info@kolinpharma.com
C.F. e P. IVA 08331990963
Cap. soc. € 1.639.571 i.v.
R.E.A. MI-2018304



www.kolinpharma.com